Hb Bart's hydrops fetalis, characterized by a complete loss of fourlinked a-globin genes due to homozygotes or compound heterozygotes of a 0 -thalassemia alleles ( À À / À À ), is the most severe form of the thalassemia syndromes. 1 Abolition of a-globin chains, which are critically required for fetal erythropoiesis to produce Hb F (a2g2), causes affected fetuses to die in utero or shortly after birth, and is associated with several maternal complications. 2, 3 In Thailand, over 5000 pregnancies each year are at risk of this condition, with 1250 new cases expected, because approximately 5-10% of Thailand's population are carriers of a 0 -thalassemia traits. 4, 5 A program for prevention and control of severe thalassemia syndromes, including Hb Bart's hydrops, was initiated in Thailand 1994. However, there are still limitations on implementation and effectiveness of this program. 5 Through the program, pregnant women are screened to identify couples at risk for severe thalassemia. Several patients with Hb Bart's hydrops were misdiagnosed and some, with or without intrauterine intervention, had survived until birth. Previous reports have shown long-term neurological deficits and a delay in mental development in surviving Hb Bart's hydrops patients. However, there is controversy about how best to manage such a condition (reviewed in the study by Higgs 1 ). We describe here a patient with Hb Bart's hydrops fetalis with normal cognitive development, 3 years after successful bone marrow transplantation.
A 33-year-old mother at 32 weeks' gestation was referred to our hospital because of toxemia of pregnancy and fetal distress. Her prenatal ultrasonography showed that the fetus had hydrops features with massive ascites. The mother received her antenatal care at a private hospital where screening for thalassemia carriers has not been implemented. Although the possibility of Hb Bart's hydrops was the most likely diagnosis, this could not be confirmed at that time, and our obstetrician decided to deliver this female fetus by cesarean section. The newborn weighed 1300 g at birth, with a Hb of 6.8 g/dL and no gross physical anomalies affecting the limbs or urogenital organs. Because of severe neonatal distress (Apgar scores of 1, 4 and 7 at 1, 5 and 10 min, respectively), she received intubation with oxygen therapy, abdominal and pleural paracentesis, and immediate total blood exchange transfusion. Hb measurement showed 100% Hb Bart's. DNA analysis confirmed the diagnosis of homozygosity for the Southeast Asian-type (SEA) deletion ( À À SEA / À À SEA ), which is the most common type of a 0 -thalassemia found in Thailand. The patient responded well to 0  1  2  3  4  5  6  9  10  11  12  13  15  16  14  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56 , ANC ( Â 1000/mL) and platelet count (Plt, Â 10 000/mL), are shown. Before admission to the transplantation unit, our patient required regular blood transfusion and this was ceased after the transplantation procedure was complete (gray box). The conditioning regimen consisted of busulfan 1.2 mg/kg per dose every 6 h intravenously and CY 50 mg/kg per day for 4 days. GVHD prophylaxis was CYA and a short course of MTX at days 1, 3, 6 and 11. Neutrophil recovery preceded that of Plts and RBCs. During the early transplantation period, the patient experienced febrile neutropenia and mucositis, which responded well to treatment. Five months after transplantation (clear box), the patient suffered from acute viral pneumonia in which her ANC and Plt count were decreased. However, Hb remained stable and she required no transfusion support. BTx ¼ blood transfusion; DLI ¼ donor lymphocyte infusion. Data are shown on a log-scale.
resuscitation and was subsequently discharged after 10 weeks in the neonatal intensive care unit, weighing 2540 g. Since the age of 3 months, the patient has received regular blood transfusion every 3-4 weeks to maintain pre-transfusion Hb at 9-10 g/dL. At the age of 19 months with a body weight of 10 600 g, she underwent matched related BMT from her older sister. Total CD 34 þ cells were 9.41 Â 10 6 cells/kg. WBC engraftment was observed on day þ 17 (after stem cell infusion) and the recipient's DNA showed full-donor chimerism on day þ 25. However, the level of chimerism changed, because mixed chimerism was observed on day þ 112 (with 41% of the recipient's DNA), albeit her Hb levels were still stable (9.1 g/dL). We decided to stop cyclosporine and provided the patient with donor lymphocyte transfusion at a dose of 1 Â 10 7 cells/kg of CD3 from her sister every 2 weeks. After five sessions of donor lymphocyte transfusion, she achieved full-donor chimerism. Clinical progression of our patient before and after SCT is shown in Figure 1 .
Currently, the patient is 4.5 years old with a Hb of 13 g/dL (Hb A, 85%; Hb A 2 , 2.5%). She has not required blood transfusion for almost 2.5 years. Physical development was normal; height and weight were at the 50th percentile according to Thai standards. We used the Mullen Scales of Early Learning: AGS Edition to comprehensively measure cognitive functioning in the patient. 6 This early learning composite score comprises performance on five subscales: gross motor (0-33 months only), fine motor, visual reception, perceptual language and expressive language. The t-scores for four cognitive skills, except for gross motor, in this patient were within the normal range (50 ± 10). The Early Learning Composite normalized score, which is an estimation of overall intelligence, was 107 (normal, 100±15), suggesting that the patient had normal cognitive and intellectual development.
Our patient had successful SCT for Hb Bart's hydrops in Southeast Asia, a region where such a condition is highly prevalent. Previously, transplantation for a cure of Hb Bart's hydrops was reported by several other groups using different sources of stem cells from matched and mismatched related BM 7 and cord blood 8 to unrelated donors. 9 However, a long-term outcome on normal growth and development was documented in only one patient at 6 years after successful transplantation. 10 Because of marked anemia in early gestation, Hb Bart's hydrops patients could further suffer from other physical complications, including limb anomalies, abnormal urogenital function and of most concern, neurological development.
1,2 Therefore, without successful transplantation, all rescued Hb Bart's hydrops would be life-long transfusion dependent with possible associated abnormalities. In our center, five surviving patients with Hb Bart's hydrops under regular transfusion had a wide range of associated anomalies. However none of them had a delay in mental or neurological development (VV, unpublished data). Such complications must be rigorously considered by physicians and parents when they decide on how to manage the affected fetus with Hb Bart's hydrops, either by early rescue by intrauterine transfusion followed by effective neonatal resuscitation or termination of pregnancy. This controversial issue of whether to 'treat' or 'not to treat' Hb Bart's hydrops warrants an international clinical registry of surviving patients with comprehensive evaluation of all related aspects. Analysis of such a database could provide evidence-based guidance for managing this condition in future cases.
